ProductUpdated on 17 September 2025
Partnership opportunity: Phase 1 ready personalized cancer vaccine
About
YG-01 is a fully individualized neoantigen based cancer vaccine designed to prevent tumor recurrence post surgery.
Neoantigens are identified with our proprietary YGNITE™ neoantigen discovery platform and coupled to our vaccine technology CARGONAUT™ to uniquely target and activate immune cells.
-
In vivo proof-of-concept demonstrated
-
GLP toxicology completed
-
GMP manufacture completed
-
Clinical Trial entry in H1 2026 in Glioblastoma
Why partner with YGION?
-
Phase 1 ready asset: Preclinical proof-of-concept, completed GLP toxicology and GMP manufacture complete for YG-01
-
Lean development plan to indicators of clinical efficacy within 3 years
-
Patent protected proprietary and differentiated neoantigen vaccine technologies
-
Application across multiple cancer types: with multi $B market opportunity
-
Experienced team: Management and advisory co-founder team with extensive biotech/Pharma leadership experience
We welcome the opportunity to meet with partners for collaboration, co-development or out-licensing partners in Japan and other global markets
Organisation
Similar opportunities
Project cooperation
- Execution
- Financing
Project cooperation